Latest Breaking News On - Philip sager - Page 1 : comparemela.com

Cardiac Safety Research Consortium Announces Think Tank Program with FDA Regulators, Industry and Academia Focused on Cardiac Remote Monitoring Trials and AI

A public-private partnership Think Tank, focused on leveraging remote monitoring for cardiac safety in clinical trials, has been announced by the Cardiac Safety Research Consortium, CSRC, in collaboration with Knobbe Martens and the University of California San Diego (UCSD) to be held Feb. 29-Mar. 1, 2024 in San Diego, CA. Representatives from the U.S. Food and Drug Administration (FDA), academia and industry will be participating in the 2-day event.

San diegoUnited statesUniversity of california san diegoSanjeev bhavnani scrippsTodd rudo clarioRajesh ghoshTodd rudoCandice taguibaoDave albert alivecorAntoniu fantanaKnobbe martensSalim idriss dukeAntoniu fantana elilillyMark mentzerRosalyn adigunPhilip sager

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study in Long QT Syndrome. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT induced

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study in Long QT Syndrome. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT induced
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomDavid huttonPhilip sagerSaumya dasThryv therapeutics incSerum glucocorticoidChief medical officerCongenital longPrincipal scientificMedical advisorThryv therapeutics

Thryv Therapeutics Inc. Announces the Presentation of Scientific Data for Its Novel SGK1 inhibitors at American Heart Association and San Antonio Breast Cancer Symposium

/PRNewswire/ - Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndrome (LQTS) via SGK1.

United statesSan antonioPhilip sagerMichael ackermanThryv therapeutics incTherapeutics incPharmacological research in cardiac electrophysiologyAmerican heart association scientific sessionsGlucocorticoid regulatedCongenital longGenotype specific re engineered heart cellsChief medical officerAction potential durationRe engineered heart cell modelsTherapeutic approachesMayo clinic

LQT Therapeutics Announces Closing of US$19M Series A Financing to Advance Lead Compound Through Phase 1 while Advancing Portfolio Assets

Press release content from PR Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesAl iskandariyahBritish columbiaDebra odinkAmzak heathAnthony rosenzweigPhilip sagerMarc vidalScott weinerSaumya dasPaulf truexAmzak healthTherapeutics incLife sciences at fondsBeth israel deacons medical center